Bristol-Myers, ImClone Partnership No Longer Threatened

02/28/2002 | Wall Street Journal, The

Bristol-Myers Squibb reportedly has abandoned its threat to break off its marketing partnership with ImClone. Fears over ImClone's cancer drug Erbitux were quelled, company officials said, after a successful meeting Tuesday between ImClone and the FDA. A source said Bristol-Myers still wants to renegotiate the partnership, but an ImClone spokesman said, "We intend to work under the existing terms."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Actuary
Meridian Health Plan
Detroit, MI
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX